BIONTECH SE - AMERICAN DEPOSITARY SHARES

BioNTech Announces Fourth Quarter and Full Year 2024 Financial Results and Corporate Update

10 мар 2025 06:55:00 Источник Nasdaq GlobeNewswire

BioNTech to Report Fourth Quarter and Full Year 2024 Financial Results and Corporate Update on March 10, 2025

24 фев 2025 06:45:00 Источник Nasdaq GlobeNewswire

BioNTech Completes Acquisition of Biotheus

03 фев 2025 06:45:00 Источник Nasdaq GlobeNewswire

BioNTech Provides Business and Pipeline Updates at 43rd Annual J.P. Morgan Healthcare Conference

14 янв 2025 06:45:00 Источник Nasdaq GlobeNewswire

BioNTech to Acquire Biotheus to Boost Oncology Strategy

13 ноя 2024 06:45:00 Источник Nasdaq GlobeNewswire

BioNTech Announces Third Quarter 2024 Financial Results and Corporate Update

04 ноя 2024 06:45:00 Источник Nasdaq GlobeNewswire

BioNTech to Host Innovation Series R&D Day on November 14, 2024

31 окт 2024 07:45:00 Источник Nasdaq GlobeNewswire

BioNTech to Report Third Quarter 2024 Financial Results and Corporate Update on November 4, 2024

21 окт 2024 06:45:00 Источник Nasdaq GlobeNewswire

BioNTech Highlights AI Capabilities and R&D Use Cases at Inaugural AI Day

01 окт 2024 06:00:00 Источник Nasdaq GlobeNewswire

Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron KP.2-adapted COVID-19 Vaccine in the European Union

20 сен 2024 08:10:00 Источник Nasdaq GlobeNewswire

BioNTech to Host AI Day as an Edition of its Innovation Series on October 1, 2024

17 сен 2024 06:45:00 Источник Nasdaq GlobeNewswire

BioNTech to Present Clinical Data Updates Across mRNA and Immunomodulatory Oncology Portfolio at ESMO Congress 2024

05 сен 2024 07:15:00 Источник Nasdaq GlobeNewswire

Pfizer and BioNTech Receive U.S. FDA Approval & Authorization for Omicron KP.2-adapted COVID-19 Vaccine

22 авг 2024 14:15:00 Источник Nasdaq GlobeNewswire

Pfizer and BioNTech Provide Update on mRNA-based Combination Vaccine Program Against Influenza and COVID-19 in Individuals 18-64 Years of Age

16 авг 2024 06:45:00 Источник Nasdaq GlobeNewswire

BioNTech Announces Second Quarter 2024 Financial Results and Corporate Update

05 авг 2024 05:59:00 Источник Nasdaq GlobeNewswire

BioNTech Announces Positive Topline Phase 2 Results for mRNA Immunotherapy Candidate BNT111 in Patients with Advanced Melanoma

30 июл 2024 06:45:00 Источник Nasdaq GlobeNewswire

BioNTech to Report Second Quarter 2024 Financial Results and Corporate Update on August 5, 2024

22 июл 2024 06:45:00 Источник Nasdaq GlobeNewswire

Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron JN.1-adapted COVID-19 Vaccine in the European Union  

27 июн 2024 10:30:00 Источник Nasdaq GlobeNewswire

BioNTech and DualityBio Receive FDA Fast Track Designation for Antibody-Drug Conjugate Candidate BNT324/DB-1311 in Prostate Cancer

24 июн 2024 06:45:00 Источник Nasdaq GlobeNewswire

Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC)

01 июн 2024 10:00:00 Источник Nasdaq GlobeNewswire